Answer
Mar 27, 2025 - 02:06 PM
Descovy is not approved for use as pre-exposure prophylaxis (PrEP) in individuals at risk of HIV from receptive xxxx sex, which primarily affects females, because its effectiveness in this population has not been adequately studied. Clinical trials for Descovy as PrEP focused on men who have sex with men and transgender women, so there is insufficient data on its efficacy for cisgender women. However, Descovy is approved for HIV treatment in all populations.
